Back HIV Populations

HIV Populations

AIDS 2016: New Strategy Aims to End AIDS in Children by 2020

A new strategy to end pediatric AIDS, launched last month at the 21st International AIDS Conference (AIDS 2016) in Durban, calls for antiretroviral treatment services to reach 1.6 million children and 1.2 million adolescents by 2018. The "Super-Fast-Track" strategy is intended to close the gap between adult and pediatric treatment access, according to UNAIDS, and will pull together the actions of numerous agencies.

alt

Read more:

AIDS 2016: South Africa Has Driven Mother-to-Child HIV Transmission Down to 4%

Mother-to-child transmission (MTCT) of HIV at a population level was just over 4% at 18 months of follow-up in a national evaluation in South Africa, Ameena Goga, presenting on behalf of the South African prevention of mother-to-child transmission Evaluation Group, told participants at the 21st International AIDS Conference (AIDS 2016) this week in Durban. 

alt

Read more:

New HIV Infections Decline by 60% Among Children in Most Affected African Countries

HIV incidence has fallen dramatically for children in the African countries with the highest burdens of the disease, more pregnant women are receiving prophylactic antiretrovirals to prevent transmission, and half of infected children are now on antiretroviral treatment, according to a new UNAIDS report release this month to coincide with the United Nations General Assembly High-Level Meeting on Ending AIDS.

alt

Read more:

AIDS 2016: HIV Treatment Programs Need to Prepare for a "Youth Bulge"

Treatment programs in sub-Saharan Africa must prepare for a growing population of adolescents over the next few years as children born with HIV grow up and begin a transition from child health services to adult clinics, Mhairi Maskew from the University of Witwatersrand told participants at the 21st International AIDS Conference (AIDS 2016) this week in Durban.

alt

Read more:

FDA Approves Dolutegravir for Smaller Children with HIV

The U.S. Food and Drug Administration this week approved a supplemental indication for the HIV integrase inhibitor dolutegravir (Tivicay), allowing its use for children age 6 years and older who weigh as little as 30 kg. The drug is currently being evaluated in younger and smaller children.

alt

Read more: